Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Oxaliplatin, and Paclitaxel in Refractory Germ Cell Carcinoma
NCT00183820Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Nov 2004
- Primary completion
- Dec 2015
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin and Paclitaxel Micelles for Injection in germ cell neoplasm (GCT) and testicular cancer, sponsored by University of Southern California. Primary endpoint: Tumor Response up to 9 years. Started Nov 2004; status: completed.
02
Drugs
gemcitabineoxaliplatinPaclitaxel Micelles for Injection
03
Conditions
germ cell neoplasm (GCT)testicular cancer
Beyond the preview
Go deeper on NCT00183820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183820.